ABSTRACT
A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.
Subject(s)
Acids, Heterocyclic/chemistry , Chemistry, Pharmaceutical/methods , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/chemistry , Receptors, Nicotinic/chemistry , Adipocytes/metabolism , Animals , Cyclic AMP/metabolism , Drug Design , Humans , Kinetics , Models, Chemical , Niacin/chemistry , Pyrazoles/chemistry , Rats , Spleen/metabolismABSTRACT
Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.
